Helping people with schizophrenia to quit smoking.

Furukawa, Toshi A

Evidence-based mental health (2015), 18(1): 14-15

2015-02

http://hdl.handle.net/2433/199658

This article has been accepted for publication in 'Evidence-based case conference' following peer review. The definitive copyedited, typeset version 'Toshi A Furukawa, Helping people with schizophrenia to quit smoking, Evid Based Mental Health 2015;18:14-15 doi:10.1136/eb-2014-102022' is available online at: http://ebmh.bmj.com/content/18/1/14.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.

Journal Article

Kyoto University
Clinical Case

Patient: 38-year-old man

Present illness: The patient developed schizophrenia in his mid-20s when he was working as a shop assistant in a busy supermarket. He was increasingly unable to concentrate, felt that he was laughed at by his colleagues and customers, and started seeing a psychiatrist after he heard voices and felt he was no longer able to control his body by his will. He has had two brief hospitalisations in the interim, had several temporary jobs but not been able to keep a steady job over a year. For the past two years he has been attending the day care centre four days a week.

Present status: He has been a heavy smoker since his 20s, smoking at least one packet a day. The consumption usually increased when he does not have a job and remained two packets a day for the past two years. Recently there was some discussion around the harms of cigarette smoking at the day care centre and he wonders if there is any medication that may help him in stopping cigarettes. He says he has tried several times on his own in vain. His present mental status mainly consists of negative symptoms (blunted affect, social withdrawal and anhedonia) and some residual positive symptoms (vague and distant auditory hallucinations). He does not suffer from substance-related disorders other than tobacco use disorder.

FORMULATE YOUR CLINICAL QUESTION

Patients: Patients with schizophrenia who smoke

Intervention: Pharmacological intervention

Comparison: Placebo

Outcomes: Continued abstinence from smoking

LITERATURE SEARCH

Ideally clinical decisions should be based on the totality of evidence and not on individual trials. You therefore start looking for a study that tries to look at the total body of evidence, a systematic review.

Being uncertain if treatments shown to help people to quit smoking in general may not
have the same effectiveness and may have different adverse effects for people with schizophrenia, you decide to look for a systematic review that specifically looked at interventions for smoking cessation among people with schizophrenia. Visiting PubMed and searching its MeSH database, you notice that “smoking cessation” is a MeSH term and you enter “smoking cessation”[mesh] and “schizophrenia”[mesh] in Clinical Queries. The second under the heading “Systematic Reviews” is a Cochrane review on this very topic. Tsoi DT, Porwal M & Webster AC (2013) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews, 2, CD007253.

**CRITICAL APPRAISAL OF A SYSTEMATIC REVIEW**

In order to appraise the totality of evidence we will follow the new Users’ Guide recently published in JAMA[1].

<table>
<thead>
<tr>
<th>First judgment: Evaluate the credibility of the methods of systematic review</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Did the review explicitly address a sensible clinical question?</strong></td>
<td></td>
</tr>
<tr>
<td>YES. The clinical question of this review may be summarised as: P: patients with schizophrenia or schizoaffective disorder</td>
<td></td>
</tr>
<tr>
<td>I: pharmacological or non-pharmacological intervention aiming at smoking cessation or reduction</td>
<td></td>
</tr>
<tr>
<td>C: another intervention, placebo or usual care</td>
<td></td>
</tr>
<tr>
<td>O: smoking cessation.</td>
<td></td>
</tr>
<tr>
<td>Our original clinical question PICO is not exactly the same as this review’s PICO but we expect that the latter covers the former, and would like to read on.</td>
<td></td>
</tr>
<tr>
<td><strong>Was the search for relevant studies exhaustive?</strong></td>
<td></td>
</tr>
<tr>
<td>YES. The review authors searched the Cochrane Tobacco Addiction Group Specialized Register and several electronic databases, in addition to clinical trials registers and handsearching. The search terms in the appendix looks comprehensive.</td>
<td></td>
</tr>
<tr>
<td><strong>Were selection and assessments of studies reproducible?</strong></td>
<td></td>
</tr>
<tr>
<td>YES/NO. The selection and assessments were done by two or more independent authors. However, the review authors do not report their reproducibility (inter-rater agreement).</td>
<td></td>
</tr>
</tbody>
</table>
Did the review present results that are ready for clinical application?

**YES.** The results were reported separately for individual interventions; only results for bupropion were summarisable in a clinically meaningful way. They are provided in forest plots as RRs and in the summary of findings table as NNTs.

Did the review address confidence in estimates of effect?

**YES.** The review authors provided enough information for the readers to judge confidence in study results, such as risks of bias for individual trials and heterogeneity among the included trials.

Second judgment: Rate the confidence in the effect estimates

**How serious is the risk of bias in the body of evidence?**

**NOT SERIOUS.** Cochrane reviews assess and present risks of bias of each included studies in the domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. The five studies included for the comparison bupropion vs placebo were judged to be mostly at either low or unclear risk of bias.

**Are the results consistent across studies?**

**YES.** The forest plot for the comparison bupropion vs placebo presents little variability from study to study, and the I² statistic was estimated to be 0%.

**How precise are the results?**

**NOT VERY PRECISE.** The pooled RR of bupropion over placebo (with or without nicotine patch) for abstinence at 6-month follow-up was 2.78 (1.02 to 7.58). While this estimate is “statistically significant,” the lower end of its 95% confidence interval is close to unity (no difference between the two arms) and would indicate no clinically meaningful benefit of bupropion over placebo. The estimate is therefore not precise.

**Do the results directly apply to my patient?**

**YES.** The average age of the included patients was in the 40s, they had been diagnosed as suffering from schizophrenia or schizoaffective disorder according to DSM-IV and had expressed interest in quitting. There appears to be no strong reason to suspect that the results of the study would not apply to the patient in the clinical
Is there concern about reporting bias?

PROBABLY NO. The number of the included studies (5 out of 7 relevant trials) is too small to statistically examine the possibility of publication bias. The literature search appears very comprehensive but in the current practice of the medical literature there always remains some doubt as to the completeness of the included evidence.

WHAT WILL YOU DO WITH YOUR PATIENT?

While the point estimate of bupropion over placebo in bringing about abstinence from smoking at 6-month follow-up appears impressive (RR=2.78), the lower limit of its confidence interval is only marginally above 1.0. Moreover, given the very low success rate in the placebo group (approximately 5%), this RR would translate into NNT of 12 (3 to 1000), using the following formulae.

\[
NNT = \frac{1}{\text{Risk difference}}
\]

\[
\text{Risk difference} = \text{Control event rate} \times \text{RR} - \text{Control event rate}
\]

where Control event rate = 5%, RR = 2.78 (and its upper or lower confidence limits).

On the other hand, this review noted that there were no significant differences in schizophrenic or depressive symptoms between bupropion and placebo. In the included trials, as reported in the literature for bupropion in general, the drug was associated with insomnia, restlessness and dry mouth among others. You conclude that there is moderate quality evidence that bupropion would bring an important yet small benefit for people with schizophrenia who smoke but who would like to quit smoking. After some discussion with you, your patient decided to give bupropion a try.

Competing interests TAF has received lecture fees from Eli Lilly, Meiji, Mochida, MSD, Pfizer and Tanabe·Mitsubishi, and consultancy fees from Sekisui and Takeda Science Foundation. He is diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku·Shoin, Seiwa·Shoten and Nihon Bunka Kagaku·sha. The Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor and Welfare, and the Japan Foundation for Neuroscience and Mental Health have
funded his research projects.

References